PIK3CB and urogenital neoplasm: Although less common, PIK3CB mutation and amplification have also been detected in clinical prostate tumor specimens (0.6–1.8% and 1.8–3.1% respectively, Tables S1–S3), and activation of p110β (encoded by PIK3CB) predisposes prostate intra-epithelial neoplasia in mice [51].